Patents by Inventor Byoung Young Woo
Byoung Young Woo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11992541Abstract: The present disclosure relates to a nanoemulsion cosmetic composition including an oil phase and an aqueous phase, wherein the oil phase contains a ginseng nanopowder and an oil swollen by the ginseng nanopowder, the composition does not contain an additional surfactant, and the ginseng nanopowder is distributed uniformly in the composition. According to the present disclosure, there is provided a nanoemulsion cosmetic composition which contains a natural substance by containing a ginseng nanopowder and an oil swollen by the ginseng nanopowder in an oil phase and provides beneficial effect to skin.Type: GrantFiled: October 27, 2021Date of Patent: May 28, 2024Assignee: AMOREPACIFIC CORPORATIONInventors: Byoung Young Woo, Yong Deog Hong, Joonyoung Hwang
-
Patent number: 11957669Abstract: One aspect of the present disclosure is a pharmaceutical composition which includes (R)—N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.Type: GrantFiled: August 10, 2018Date of Patent: April 16, 2024Assignee: AMOREPACIFIC CORPORATIONInventors: Joon Ho Choi, Won Kyung Cho, Kwang-Hyun Shin, Byoung Young Woo, Ki-Wha Lee, Min-Soo Kim, Jong Hwa Roh, Mi Young Park, Young-Ho Park, Eun Sil Park, Jae Hong Park
-
Patent number: 11878008Abstract: Disclosed is a method for preventing or treating atopic dermatitis using TRPV1 receptor antagonist. More specifically, it may be possible to prevent and/or treat the atopic dermatitis without any side effects such as an increase in body temperature, epidermal atrophy, and the like by percutaneously administrating a composition for external use on the skin containing the TRPV1 receptor antagonist.Type: GrantFiled: February 28, 2020Date of Patent: January 23, 2024Assignee: AMOREPACIFIC CORPORATIONInventors: Gyeyoung Choi, Hyunjin Nam, Miyoung Park, Kyoungmi Jung, Jihae Lee, Chang Soon Choi, Youngho Park, Jong Hwa Roh, Eunsil Park, Jaehong Park, Kwanghyun Shin, Byoung Young Woo, Kiwha Lee, Wonkyung Cho, Joonho Choi
-
Patent number: 11382900Abstract: Disclosed is a method for preventing or treating sleep disorders using TRPV1 receptor antagonist, (R)—N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide. The method of the present invention can effectively and safely prevent or treat sleep disorders accompanying pruritus caused by atopic dermatitis.Type: GrantFiled: February 28, 2020Date of Patent: July 12, 2022Assignee: AMOREPACIFIC CORPORATIONInventors: Gyeyoung Choi, Hyunjin Nam, Miyoung Park, Kyoungmi Jung, Jihae Lee, Chang Soon Choi, Youngho Park, Jong Hwa Roh, Eunsil Park, Jaehong Park, Kwanghyun Shin, Byoung Young Woo, Kiwha Lee, Wonkyung Cho, Joonho Choi
-
Publication number: 20220125692Abstract: The present disclosure relates to a nanoemulsion cosmetic composition including an oil phase and an aqueous phase, wherein the oil phase contains a ginseng nanopowder and an oil swollen by the ginseng nanopowder, the composition does not contain an additional surfactant, and the ginseng nanopowder is distributed uniformly in the composition. According to the present disclosure, there is provided a nanoemulsion cosmetic composition which contains a natural substance by containing a ginseng nanopowder and an oil swollen by the ginseng nanopowder in an oil phase and provides beneficial effect to skin.Type: ApplicationFiled: October 27, 2021Publication date: April 28, 2022Applicant: AMOREPACIFIC CORPORATIONInventors: Byoung Young WOO, Yong Deog HONG, Joonyoung HWANG
-
Publication number: 20220125709Abstract: The present disclosure relates to a ginseng powder, a cosmetic composition containing the same and a method for preparing the same. The present disclosure provides a ginseng powder with superior dissolution rate of active ingredients even at relatively low temperature. Therefore, the present disclosure provides an effect that the active ingredients contained in ginseng can be utilized effectively.Type: ApplicationFiled: October 27, 2021Publication date: April 28, 2022Applicant: AMOREPACIFIC CORPORATIONInventors: Byoung Young WOO, Hyungmin KIM, Sejun PARK, Somi LEE, Yong Deog HONG
-
Publication number: 20220000775Abstract: One aspect of the present disclosure relates to a sol-gel composition enabling reversible sol-gel transition and, more specifically, to a sol-gel composition of which the viscosity changes by external physical force so that reversible sol-gel transition is performed.Type: ApplicationFiled: October 16, 2019Publication date: January 6, 2022Applicant: Amorepacific CorporationInventors: Wonkyung CHO, Kwanghyun SHIN, Joonho CHOI, Kiwha LEE, Jong Hwa ROH, Miyoung PARK, Youngho PARK, Eunsil PARK, Jaehong PARK, Byoung Young WOO, Min Soo KIM, Eun Sol HA
-
Publication number: 20200405701Abstract: One aspect of the present disclosure relates to a pharmaceutical composition, containing (R)-N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first ingredient and containing a vinylpyrrolidone-based polymer as a second ingredient. The composition of one aspect of the present disclosure has a formulation characteristic in which the crystal formation of a compound represented by chemical formula 1 is delayed for a long time.Type: ApplicationFiled: March 21, 2019Publication date: December 31, 2020Applicant: Amorepacific CorporationInventors: Joonho CHOI, Wonkyung CHO, Jong Hwa ROH, Kwanghyun SHIN, Byoung Young WOO, Min Soo KIM, Miyoung PARK, Youngho PARK, Eunsil PARK, Jaehong PARK, Kiwha LEE
-
Patent number: 10858315Abstract: Disclosed in the present specification is a method capable of preparing N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide (INT028-2) with high optical purity, through the selection of Ellman-chiral auxiliaries and the recrystallization and separation of optical isomers. According to the above method, high-purity N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide with excellent quality can be produced at room temperature by improving cryogenic process conditions necessary for realizing high optical purity, and thus the trimming due to the process failure rate can be remarkably reduced.Type: GrantFiled: September 26, 2017Date of Patent: December 8, 2020Assignee: AMOREPACIFIC CORPORATIONInventors: Byoung Young Woo, Ki-Wha Lee, Jihae Lee, Chang Soon Choi, Miyoung Park, Young-Ho Park, Sarva Jayaprakash, Sridhar Regati, Mamidi Srinivas, Krushnakant Patel, M. Ramamohan
-
Publication number: 20200215040Abstract: One aspect of the present disclosure is a pharmaceutical composition which includes (R)—N-[1-(3,5-difluoro-4-methansulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide as a first component and a cellulosic polymer as a second component, wherein the composition of one aspect of the present disclosure has a formulation characteristic in which crystal formation is delayed for a long time.Type: ApplicationFiled: August 10, 2018Publication date: July 9, 2020Applicant: AMOREPACIFIC CORPORATIONInventors: Joon Ho CHOI, Won Kyung CHO, Kwang-Hyun SHIN, Byoung Young WOO, Ki-Wha LEE, Min-Soo KIM, Jong Hwa ROH, Mi Young PARK, Young-Ho PARK, Eun Sil PARK, Jae Hong PARK
-
Patent number: 10696611Abstract: Disclosed is a novel adamantine derivative compound, an isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or a solvate thereof. Also disclosed is a method for preparing a novel adamantine derivative compound, an isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or a solvate thereof. The novel adamantane derivative compound or the like has an excellent anti-androgenic effect.Type: GrantFiled: August 24, 2015Date of Patent: June 30, 2020Assignee: AMOREPACIFIC CORPORATIONInventors: Yung Hyup Joo, Song Seok Shin, Byoung Young Woo, Heung Soo Baek, Yong Deog Hong, Hong-Ju Shin, Yeon Su Jeong, Jon Hwan Lee
-
Publication number: 20200197378Abstract: Disclosed is a method for preventing or treating sleep disorders using TRPV1 receptor antagonist, (R)—N-[1-(3,5-difluoro-4-methanesulfonylamino-phenyl)-ethyl]-3-(2-propyl-6-trifluoromethyl-pyridin-3-yl)-acrylamide. The method of the present invention can effectively and safely prevent or treat sleep disorders accompanying pruritus caused by atopic dermatitis.Type: ApplicationFiled: February 28, 2020Publication date: June 25, 2020Applicant: AMOREPACIFIC CORPORATIONInventors: Gyeyoung CHOI, Hyunjin NAM, Miyoung PARK, Kyoungmi JUNG, Jihae LEE, Chang Soon CHOI, Youngho PARK, Jong Hwa ROH, Eunsil PARK, Jaehong PARK, Kwanghyun SHIN, Byoung Young WOO, Kiwha LEE, Wonkyung CHO, Joonho CHOI
-
Publication number: 20200197379Abstract: Disclosed is a method for preventing or treating atopic dermatitis using TRPV1 receptor antagonist. More specifically, it may be possible to prevent and/or treat the atopic dermatitis without any side effects such as an increase in body temperature, epidermal atrophy, and the like by percutaneously administrating a composition for external use on the skin containing the TRPV1 receptor antagonist.Type: ApplicationFiled: February 28, 2020Publication date: June 25, 2020Applicant: AMOREPACIFIC CORPORATIONInventors: Gyeyoung CHOI, Hyunjin NAM, Miyoung PARK, Kyoungmi JUNG, Jihae LEE, Chang Soon CHOI, Youngho PARK, Jong Hwa ROH, Eunsil PARK, Jaehong PARK, Kwanghyun SHIN, Byoung Young WOO, Kiwha LEE, Wonkyung CHO, Joonho CHOI
-
Publication number: 20200031766Abstract: Disclosed in the present specification is a method capable of preparing N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide (INT028-2) with high optical purity, through the selection of Ellman-chiral auxiliaries and the re-crystallization and separation of optical isomers. According to the above method, high-purity N-[4-[(1R)-1-[[(R)-(1,1-dimethylethyl)sulfinyl]amino]ethyl]-2,6-difluorophenyl]-methanesulfonamide with excellent quality can be produced at room temperature by improving cryogenic process conditions necessary for realizing high optical purity, and thus the trimming due to the process failure rate can be remarkably reduced.Type: ApplicationFiled: September 26, 2017Publication date: January 30, 2020Applicant: Amorepacific CorporationInventors: Byoung Young WOO, Ki-Wha LEE, Jihae LEE, Chang Soon CHOI, Miyoung PARK, Young-Ho PARK, Sarva JAYAPRAKASH, Sridhar REGATI, Mamidi SRINIVAS, Krushnakant PATEL, M. RAMAMOHAN
-
Patent number: 10479763Abstract: The present specification relates to a chiral resolution method of a stereoisomer mixture, comprising a step of mixing a stereoisomer mixture of compounds, in which an amine group is bound to an asymmetric carbon atom, with a chiral auxiliary and salt-forming auxiliary compound, wherein the chiral auxiliary is an O,O?-diacyltartaric acid derivative, more specifically, a 2,3-dibenzoyl-tartaric acid or O,O?-di-p-toluoyl tartaric acid, the salt-forming auxiliary compound is mandelic acid or camphorsulfonic acid, and an optical isomer having a high level of optical purity can be obtained by using the method. Therefore, according to one aspect of the present invention, the method can be useful in pharmaceutical or cosmetic field when preparing an optical isomer having a high optical purity.Type: GrantFiled: February 15, 2016Date of Patent: November 19, 2019Assignee: AMOREPACIFIC CORPORATIONInventors: Byoung Young Woo, Ki-Wha Lee, Kwang-Hyun Shin, Miyoung Park, Kyoungmi Jung, Joonho Choi, Gyeyoung Choi, Wonkyung Cho, Young-Ho Park
-
Publication number: 20170342027Abstract: The present specification relates to a chiral resolution method of a stereoisomer mixture, comprising a step of mixing a stereoisomer mixture of compounds, in which an amine group is bound to an asymmetric carbon atom, with a chiral auxiliary and salt-forming auxiliary compound, wherein the chiral auxiliary is an O,O?-diacyltartaric acid derivative, more specifically, a 2,3-dibenzoyl-tartaric acid or O,O?-di-p-toluoyl tartaric acid, the salt-forming auxiliary compound is mandelic acid or camphorsulfonic acid, and an optical isomer having a high level of optical purity can be obtained by using the method. Therefore, according to one aspect of the present invention, the method can be useful in pharmaceutical or cosmetic field when preparing an optical isomer having a high optical purity.Type: ApplicationFiled: February 15, 2016Publication date: November 30, 2017Applicant: AMOREPACIFIC CORPORATIONInventors: Byoung Young WOO, Ki-Wha LEE, Kwang-Hyun SHIN, Miyoung PARK, Kyoungmi JUNG, Joonho CHOI, Gyeyoung CHOI, Wonkyung CHO, Young-Ho PARK
-
Publication number: 20170283347Abstract: Disclosed is a novel adamantine derivative compound, an isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or a solvate thereof. Also disclosed is a method for preparing a novel adamantine derivative compound, an isomer thereof, pharmaceutically acceptable salt thereof, prodrug thereof, hydrate thereof or a solvate thereof. The novel adamantane derivative compound or the like has an excellent anti-androgenic effect.Type: ApplicationFiled: August 24, 2015Publication date: October 5, 2017Inventors: Yung Hyup JOO, Song Seok SHIN, Byoung Young WOO, Heung Soo BAEK, Yong Deog HONG, Hong-Ju SHIN, Yeon Su JEONG, Jon Hwan LEE
-
Publication number: 20150290099Abstract: The present invention provides: a novel pseudoceramide compound, an isomer thereof, a pharmaceutically acceptable salt thereof, a prodrug thereof, a hydrate thereof or a solvate thereof. The present invention has a skin protecting effect in that the invention has a superior effect in skin moisturisation and is outstandingly stable and soluble, and thus the invention can protect the skin from external irritation without side effects, and can be used as an active substance in damaged skin recovery and prevention. Consequently, the invention can be used as a skin-moisturising dermatological external composition, cosmetic composition or pharmaceutical composition.Type: ApplicationFiled: November 29, 2013Publication date: October 15, 2015Inventors: Byoung Young Woo, Won Hee Jang, Yung Hyup Joo, Yang Hui Park, Chang Geun Yi, Young Suk Cho, Heung Soo Baek, Song Seok Shin, Young Ho Park
-
Patent number: 8691855Abstract: This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present invention provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.Type: GrantFiled: July 2, 2009Date of Patent: April 8, 2014Assignee: Amorepacific CorporationInventors: Byoung Young Woo, Sun-Young Kim, Yeonjoon Kim, Song Seok Shin, Jin Kwan Kim, Ki-Wha Lee, Dong Hyun Kim, Kyung Min Lim, Joo-Hyun Moh, Yeon Su Jeong, Jin Kyu Choi, Hyun Ju Koh, Jeongho Lee, Hyuk Kim, Jeong Hoon Yoon, Funan Li, Jee-Suk Kim, Young-Ger Suh
-
Publication number: 20140011881Abstract: This present disclosure relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The present disclosure provides a pharmaceutical composition for preventing or treating a disease such as pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorder, urinary bladder hypersensitiveness, irritable bowel syndrome, fecal urgency, a respiratory disorder, irritation of skin, eye or mucous membrane, stomach-duodenal ulcer, inflammatory diseases, ear disease, heart disease and so on.Type: ApplicationFiled: September 10, 2013Publication date: January 9, 2014Applicant: Amorepacific CorporationInventors: Song Seok SHIN, Jin Kwan KIM, Sun-Young KIM, Ki-Wha LEE, Byoung young WOO, Joo-Hyun MOH, Yeon Su JEONG, Kyung Min LIM, Jin Kyu CHOI, Hyun-Ju KOH, Young-Ho PARK